A study found that corona patients who received the treatment increased their chances of improving their clinical condition by 65%.

• The treatment was also approved for mild and moderate patients

  Photo: 

  IP

Fighting Corona Epidemic in the United States: The drug Ramsesibir for the treatment of viral patients will also be given in the United States to mild and moderate patients hospitalized.

So far the treatment is given only in severe patients, respirators or with a decrease in oxygen saturation in the blood. The drug is now approved for use in the United States even in patients in mild and moderate condition who are hospitalized. It should be noted that in Israel the drug is given only to critically ill patients in hospitals. After the first wave, there was a shortage of medicine, but Israel purchased additional stock.

The expansion of use in the U.S. came in the wake of a study published in the August issue of the journal JAMA.

Archive photo: Reuters

Giving the treatment for five days increased by 65% ​​the chances of the patients to improve in the symptoms of the disease and in the indices - discharge from the hospital and an increase in the level of oxygen in the blood. Treatment appears to be beneficial for the symptoms of the disease, but it has not yet proven effective in the mortality index.

However, in the group that received treatment in Ramadan Siberia for ten days, a 31% improvement was found in the chance of improvement in clinical symptoms. In addition, the improvement is not significant.

"Data show that this treatment has the potential to help more hospitalized patients suffering from the effects of this destructive virus, and the potential to help more hospitalized patients," said FDA Commissioner Dr. Stephen Hahn.

Dr. Francisco Marty, an infectious disease specialist at Harvard Medical School who conducted the study, noted: “Our understanding of the spectrum of Corona virus infection and the severity of the disease continues to evolve. The results of the study and the approval that can be given for emergency use of the drug, are a new and important step that allows to give the hospitalized patient the treatment in Remedial without waiting for aggravation of his clinical condition. The results of the study show that corona patients in moderate condition may benefit from five days of treatment in Ramadan Siberia. "

It should be emphasized that the study found that the side effects of the treatment were nausea, diarrhea and headaches. In contrast, another study conducted by the U.S. National Institute of Allergy and Infectious Diseases found that treatment with Remedysvir shortened the duration of recovery from 15 days to ten days.

Remedial Siberia is an antiviral drug, which shortens the length of time the virus replicates in the body. The drug was developed by the pharmaceutical company Gilad, which operates on the replication mechanism of the corona virus. It has been shown to be effective in laboratory conditions on other viruses from the corona family - SARS and MERS and therefore many expectations were placed on it.